{"product_id":"quantitative-drug-safety-and-benefit-risk-evaluation-practical-and-crossdisciplinary-approaches-9781032191119","title":"Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches","description":"\u003cp\u003e\u003c\/p\u003e\u003cblockquote\u003e\n\u003cbr\u003eQuantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation provides a comprehensive coverage on safety monitoring methodologies, covering both global trends and regional initiatives. It aims to bridge the gap in knowledge between medical and statistical fields and create a multi-disciplinary approach for 21st-century safety evaluation. \u003c\/blockquote\u003e\u003cp\u003e\u003cstrong\u003eFormat\u003c\/strong\u003e: Paperback \/ softback\u003cbr\u003e\u003cstrong\u003eLength\u003c\/strong\u003e: 382 pages\u003cbr\u003e\u003cstrong\u003ePublication date\u003c\/strong\u003e: 29 January 2024\u003cbr\u003e\u003cstrong\u003ePublisher\u003c\/strong\u003e: Taylor \u0026amp; Francis Ltd\u003cbr\u003e\u003c\/p\u003e \u003cp\u003e\u003cbr\u003eQuantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation is a comprehensive guide that delves into the realm of safety monitoring methodologies, encompassing both global trends and regional initiatives. Traditionally, pharmacovigilance has primarily focused on the handling of individual adverse event reports. However, in recent years, there has been a notable shift towards aggregate analysis, aimed at gaining a deeper understanding of the broader scope of product risks. This book, written with the intention of being accessible to both statisticians and safety scientists with a quantitative interest, seeks to bridge the knowledge gap between the medical and statistical fields, fostering a truly multi-disciplinary approach that is essential for safety evaluation in the 21st century.\u003cbr\u003e\u003cbr\u003eThe book begins by providing an overview of the various safety monitoring methodologies, including both traditional approaches and emerging technologies. It discusses the importance of monitoring and evaluating safety throughout the drug development and approval process, as well as during post-marketing surveillance. It also highlights the role of risk management in ensuring the safe and effective use of pharmaceutical products.\u003cbr\u003e\u003cbr\u003eIn the subsequent chapters, the book explores in detail the various quantitative methodologies used in safety monitoring and ongoing benefit risk evaluation. It covers topics such as adverse event reporting, signal detection, risk assessment, and decision-making under uncertainty. The authors provide practical examples and case studies to illustrate the application of these methodologies in real-world scenarios.\u003cbr\u003e\u003cbr\u003eOne of the key strengths of the book is its multidisciplinary approach. It brings together experts from various fields, including medicine, statistics, and risk management, to provide a comprehensive understanding of safety monitoring and ongoing benefit risk evaluation. This approach ensures that the readers gain a holistic perspective on the topic, enabling them to apply the knowledge and techniques in their respective fields.\u003cbr\u003e\u003cbr\u003eAnother notable feature of the book is its emphasis on the use of real-world data and evidence-based decision-making. The authors highlight the importance of leveraging data from various sources, such as clinical trials, post-marketing surveillance, and patient registries, to inform safety monitoring and risk evaluation decisions. They also discuss the challenges and limitations associated with using these data sources and provide strategies for overcoming them.\u003cbr\u003e\u003cbr\u003eThroughout the book, the authors emphasize the importance of transparency and accountability in safety monitoring and ongoing benefit risk evaluation. They advocate for the development of robust regulatory frameworks and guidelines that promote the use of evidence-based decision-making and ensure the safety and effectiveness of pharmaceutical products.\u003cbr\u003e\u003cbr\u003eIn conclusion, Quantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation is a valuable resource for anyone involved in safety monitoring and ongoing benefit risk evaluation. It provides a comprehensive coverage of the various quantitative methodologies used in safety monitoring, as well as the broader context of safety evaluation in the pharmaceutical industry. The multidisciplinary approach, emphasis on real-world data, and emphasis on transparency and accountability make this book an essential read for professionals across the healthcare and pharmaceutical sectors.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWeight\u003c\/strong\u003e: 453g\u003cbr\u003e\u003cstrong\u003eDimension\u003c\/strong\u003e: 234 x 156 (mm)\u003cbr\u003e\u003cstrong\u003eISBN-13\u003c\/strong\u003e: 9781032191119\u003c\/p\u003e","brand":"Shulph Ink","offers":[{"title":"Paperback \/ softback","offer_id":45179503476986,"sku":"9781032191119","price":52.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0522\/4297\/2845\/products\/noImage_1_da562d93-22c6-4a4a-a48f-cbf4945a8507.jpg?v=1707754589","url":"https:\/\/shulphink.com\/products\/quantitative-drug-safety-and-benefit-risk-evaluation-practical-and-crossdisciplinary-approaches-9781032191119","provider":"Shulph Ink","version":"1.0","type":"link"}